Chengzhi Co (000990) Fair Value & Analysis
Healthcare · CN · Market cap 11.0B CNY
Fair value as of: Jun 25, 2026
From 14 valuation models · updated 5 days ago
Share price −14.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥7.69 – ¥14.00 · fair‑value band ¥1.97 – ¥9.15 · the ¥8.80 price screens above the ¥4.62 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Chengzhi Co (000990) currently trades at ¥8.80, while our model-based Fair Value estimate is ¥4.62 — implying the stock looks roughly 47.5% overvalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Chengzhi Co generated revenue of 10.9B CNY at a net margin of 0.7%. Revenue declined 5.4% year over year. It earns a return on equity of 1.3%. Net debt stands at 3.8B CNY. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Chengzhi Co., Ltd. engages in the clean energy, semiconductor display material, and healthcare and life science businesses in China. The company produces and sells gas products, including carbon monoxide, purified gas, and syngas, as well as industrial chemical products, such as methanol, ethylene, and butanol. It also processes materials comprising TN type, STN type, and TFT type; and glass processing for displays, d-ribose, arbutin, lipox, and d-ribose powder. In addition, the company is involved in production and sales of biopharmaceuticals and pharmaceutical intermediates; related trade in chemical raw materials; and provision of medical and health services. The company was founded in 1998 and is headquartered in Nanchang, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Chengzhi Co reported revenue of ¥11.0B in FY2025 versus ¥12.2B in FY2021, a compound −2.5%/yr. Reported net income was −¥78.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$607.20 | R$74.60 | -88% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Chengzhi Co (000990) undervalued?
What is the fair value of 000990?
What is the quality score of 000990?
What is the revenue of Chengzhi Co (000990)?
What is the net profit margin of 000990?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.